S100A8 and COVID-19: Accordingly, therapeutic agents targeting S100a8-TLR4 or S100a9 can alleviate inflammatory responses and improve survival in preclinical models of SARS-CoV-2 infection (13), thereby emphasizing the clinical significance of calprotectin in COVID-19 pathogenesis (7, 10, 14).